GlassScriptPhysician profile
Michael R Rabinowitz
NPI 1619979978
$6,902.02
in general payments reported to CMS, 2019-2025
43 companies · $780 in 2025
The $780 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,150 · 2020: $918 · 2021: $1,473 · 2022: $752 · 2023: $1,098 · 2024: $731 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,601 · Education: $8.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,600.76 |
| Education | $8.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,461.10 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $869.70 | 2020-2024 | Xifaxan |
| Novo Nordisk INC | $718.78 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $576.78 | 2019-2024 | Farxiga, Lokelma |
| Lilly USA, LLC | $555.68 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Merck Sharp & Dohme LLC | $448.44 | 2019-2022 | |
| Abbvie INC. | $330.27 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.59 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $188.18 | 2019-2023 | |
| Allergan, INC. | $140.78 | 2020 | |
| Pfizer INC. | $105.15 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $98.02 | 2019-2023 | Rexulti |
| Amgen INC. | $97.85 | 2020-2025 | Otezla, Repatha, Repatha |
| Phathom Pharmaceuticals, INC. | $88.59 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.01 | 2024-2025 | Caplyta |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rabinowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.